Samir K Gupta

Summary

Affiliation: Schering-Plough Research Institute
Country: USA

Publications

  1. ncbi Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment
    Samir K Gupta
    Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    J Clin Pharmacol 47:1283-91. 2007
  2. pmc Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia
    Samir Gupta
    Schering Plough Research Institute, Kenilworth, NJ, USA
    Br J Clin Pharmacol 63:292-9. 2007
  3. pmc Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults
    Samir K Gupta
    Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Br J Clin Pharmacol 64:174-84. 2007
  4. ncbi The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy
    Samir K Gupta
    MBA, Schering Plough Research Institute K15 22745, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    J Clin Pharmacol 47:604-12. 2007
  5. pmc Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects
    Samir K Gupta
    Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Br J Clin Pharmacol 56:131-4. 2003
  6. pmc Pharmacokinetics of desloratadine in children between 2 and 11 years of age
    Samir Gupta
    Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Br J Clin Pharmacol 63:534-40. 2007
  7. pmc Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency
    Samir K Gupta
    Schering Plough Research Institute, Kenilworkth, NJ 07033, USA
    Br J Clin Pharmacol 64:726-32. 2007
  8. doi Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C
    Samir K Gupta
    Schering Plough Research Institute, K15 22745 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Eur J Clin Pharmacol 67:591-9. 2011
  9. ncbi Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction
    Samir K Gupta
    Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    J Clin Pharmacol 42:1109-15. 2002
  10. ncbi Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment
    Samir K Gupta
    Departments of Drug Metabolism Pharmacokinetics and Clinical Pharmacology, Merck Research Lab, Kenilworth, NJ, USA
    Drug Discov Ther 7:158-63. 2013

Collaborators

Detail Information

Publications23

  1. ncbi Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment
    Samir K Gupta
    Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    J Clin Pharmacol 47:1283-91. 2007
    ..Poor metabolizers had more exposure to desloratadine than normal metabolizers with or without hepatic impairment. Desloratadine administered at a daily dose of 5 mg was well tolerated...
  2. pmc Dose selection and population pharmacokinetics of PEG-Intron in patients with chronic myelogenous leukaemia
    Samir Gupta
    Schering Plough Research Institute, Kenilworth, NJ, USA
    Br J Clin Pharmacol 63:292-9. 2007
    ..To assess the dose selection using population pharmacokinetics of Pegylated Intron-alpha2b (PEG-Intron) in patients with chronic myelogenous leukaemia (CML)...
  3. pmc Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults
    Samir K Gupta
    Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Br J Clin Pharmacol 64:174-84. 2007
    ..The aim of this study was to identify the dose of desloratadine in children aged > or =6 months- < or =2 years that would yield a single-dose target exposure (AUC) comparable with that in adults taking 5 mg desloratadine as syrup...
  4. ncbi The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy
    Samir K Gupta
    MBA, Schering Plough Research Institute K15 22745, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    J Clin Pharmacol 47:604-12. 2007
    ....
  5. pmc Single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b in young and elderly healthy subjects
    Samir K Gupta
    Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Br J Clin Pharmacol 56:131-4. 2003
    ..To assess the single-dose pharmacokinetics and tolerability of pegylated interferon-alpha2b (PEG-Intron) in young and elderly healthy subjects...
  6. pmc Pharmacokinetics of desloratadine in children between 2 and 11 years of age
    Samir Gupta
    Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Br J Clin Pharmacol 63:534-40. 2007
    ..The aim of the studies was to characterize the pharmacokinetics of desloratadine in healthy children and to determine the appropriate dose for paediatric patients 2-11 years old...
  7. pmc Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency
    Samir K Gupta
    Schering Plough Research Institute, Kenilworkth, NJ 07033, USA
    Br J Clin Pharmacol 64:726-32. 2007
    ..To evaluate the safety, tolerability and multiple-dose pharmacokinetics of pegylated interferon (PEG-IFN) alfa-2b in patients with moderate or severe renal insufficiency and in those with normal renal function...
  8. doi Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C
    Samir K Gupta
    Schering Plough Research Institute, K15 22745 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Eur J Clin Pharmacol 67:591-9. 2011
    ..To examine the effect of pegylated interferon (PEG-IFN) alfa-2b on the activity of major drug-metabolizing enzymes...
  9. ncbi Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction
    Samir K Gupta
    Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    J Clin Pharmacol 42:1109-15. 2002
    ..Based on the relationship between PEG-Intron apparent clearance and CL(CR), renal clearance accountsfor less than half of its total clearance. Hemodialysis did not affect PEG-Intron apparent clearance...
  10. ncbi Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment
    Samir K Gupta
    Departments of Drug Metabolism Pharmacokinetics and Clinical Pharmacology, Merck Research Lab, Kenilworth, NJ, USA
    Drug Discov Ther 7:158-63. 2013
    ..The pharmacokinetics of ribavirin were substantially altered in subjects with stable chronic renal impairment, possibly reflecting changes in ribavirin metabolism associated with renal impairment...
  11. doi Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients
    Samir K Gupta
    Departments of Drug Metabolism, Merck Research Laboratory, Kenilworth, NJ, USA
    Eur J Clin Pharmacol 68:415-8. 2012
    ..This study describes the pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients...
  12. ncbi Oral bioavailability of desloratadine is unaffected by food
    Samir Gupta
    Schering Plough Research Institute, Kenilworth, New Jersey 07033 0539, USA
    Clin Pharmacokinet 41:7-12. 2002
    ..To determine the effect of coadministration of food on the bioavailability of oral desloratadine...
  13. ncbi Metabolism of loratadine and further characterization of its in vitro metabolites
    Anima Ghosal
    Pharmaceutical Sciences and Drug Metabolism, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Drug Metab Lett 3:162-70. 2009
    ..The relative abundance of CYP3A4 in the human liver exceeds that of CYP2C19 and CYP2D6 and therefore the contribution of CYP3A4 in the metabolism of loratadine should be major (approximately 70%)...
  14. ncbi Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine
    Christopher Banfield
    Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, K 15 4 4455, NJ 07033, USA
    Clin Pharmacokinet 41:311-8. 2002
    ..These effects may be mediated by interactions with enzyme systems, such as cytochrome P450, or with active transporter systems, such as P-glycoprotein and organic anion transporting polypeptides...
  15. ncbi A pharmacokinetic profile of desloratadine in healthy adults, including elderly
    Melton Affrime
    Schering Plough Research Institute, Kenilworth, New Jersey 07033 0539, USA
    Clin Pharmacokinet 41:13-9. 2002
    ....
  16. ncbi Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine
    Melton Affrime
    Schering Plough Research Institute, Kenilworth, New Jersey 07033 0539, USA
    Clin Pharmacokinet 41:21-8. 2002
    ..This study was designed to characterise the single and multiple dose pharmacokinetic profile of desloratadine, a new antihistamine, and its main metabolite, 3-hydroxy (3-OH) desloratadine, in healthy volunteers differing in sex and race...
  17. ncbi Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models
    Juif Jen
    Department of Statistics, Schering Plough Research Institute, Kenilworth, NJ, USA
    Clin Pharmacol Ther 72:349-61. 2002
    ..Approved ribavirin dosages vary from a fixed dosage of 800 mg/d to as much as 1200 mg/d on the basis of body weight...
  18. ncbi Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers
    Samir Gupta
    Schering Plough Research Institute, K15 22745, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    J Clin Pharmacol 44:1252-9. 2004
    ..The most common adverse event in all groups was headache (65%). Desloratadine plus fluoxetine caused no significant changes in ECGs or ventricular rate...
  19. ncbi Desloratadine demonstrates dose proportionality in healthy adults after single doses
    Samir Gupta
    Schering Plough Research Institute, Kenilworth, New Jersey 07033 0539, USA
    Clin Pharmacokinet 41:1-6. 2002
    ..To evaluate the dose proportionality and linearity and pharmacokinetic profile of desloratadine after single oral doses over the range of 5 to 20mg...
  20. ncbi Exogenous cushing syndrome mimicking human immunodeficiency virus lipodystrophy
    Samir K Gupta
    Division of Infectious Diseases, Indiana University School of Medicine, Wishard Memorial Hospital, Indianapolis, IN, 46202, USA
    Clin Infect Dis 35:E69-71. 2002
    ..Clinicians should be aware that clinical clues may indicate conditions other than lipodystrophy that may cause abnormal fat accumulation and that fluticasone should be cautiously administered to patients who are receiving ritonavir...
  21. ncbi Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study
    Ronald Bukowski
    Experimental Therapeutics Program, Cleveland Clinic Cancer Center, Cleveland, OH 44195, USA
    J Clin Oncol 20:3841-9. 2002
    ....
  22. ncbi SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders
    Christoph Sarrazin
    Department of Internal Medicine II, Saarland University Hospital, Homburg, Germany
    Gastroenterology 132:1270-8. 2007
    ....
  23. ncbi Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
    Samir K Gupta
    Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Clin Infect Dis 40:1559-85. 2005